PULMICORT TURBUHALER 200MCG/DOSE

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

BUDESONIDE

Boleh didapati daripada:

ASTRAZENECA SDN. BHD.

INN (Nama Antarabangsa):

BUDESONIDE

Unit dalam pakej:

100Units Units

Dikeluarkan oleh:

ASTRAZENECA AB

Risalah maklumat

_ CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
PULMICORT TURBUHALER
Budesonide (100 mcg/dose & 200 mcg/dose)
_ _
1
WHAT IS IN THIS LEAFLET
1.
What Pulmicort Turbuhaler
is used for
2.
How Pulmicort Turbuhaler
works
3.
Before
you
use
Pulmicort
Turbuhaler
4.
How
to
use
Pulmicort
Turbuhaler
5.
While you are using it
6.
Side effects
7.
Storage
&
Disposal
of
Pulmicort Turbuhaler
8.
Product Description
9.
Manufacturer
&
Product
Registration Holder
10.
Date of Revision
READ
ALL
OF
THIS
LEAFLET
CAREFULLY
BEFORE
YOU
START
USING THIS MEDICINE.
•
Keep this leaflet. You may
need to read it again.
•
If
you
have
any
further
questions, ask your doctor
or pharmacist.
•
This
medicine
has
been
prescribed for you. Do not
pass it on to others. It may
harm them, even if their
symptoms are the same as
yours.
•
If any of the side effects
gets
serious,
or
if
you
notice any side effects not
listed in this leaflet, please
tell
your
doctor
or
pharmacist.
WHAT PULMICORT TURBUHALER
IS USED FOR
Pulmicort
Turbuhaler
is
used
for
the
regular
treatment
of
asthma.
_ _
HOW
PULMICORT
TURBUHALER
WORKS
Pulmicort
Turbuhaler
relieves
and prevents inflammation in
the airways caused by asthma.
Pulmicort
Turbuhaler
is
intended
for
regular
use
and
not
for
rapid
relief
of
acute
asthma conditions. It may take
some weeks before you receive
the full effect of the treatment.
BEFORE
YOU
USE
PULMICORT
TURBUHALER
_- When you must not use it _
Do
not
use
Pulmicort
Turbuhaler if you are allergic
(hypersensitive) to budesonide.
_- Before you start to use it _
If
you
switch
from
cortisone
tablets
to
Pulmicort
Turbuhaler,
as
your
previous
allergic
symptoms
such
as
a
runny
nose
and
eczema
may
return
in
certain
cases.
You
may also experience tiredness,
headaches,
muscle
and
joint
pain
and
occasionally
nausea
and vomiting. This is because
the total amount of cortisone in
the body is reduced when the
disease is treated locally in the
lungs.
These
symptoms
disappear
after
you
have
received
treatment
for
some
time.
It
is
important
that
you
tell
your
doctor
if
you

Ciri produk

1
PULMICORT TURBUHALER 100 AND 200 MICROGRAMS/DOSE
_BUDESONIDE _
Inhalation powder
QUALITATIVE AND QUANTITATIVE COMPOSITION
One metered dose contains budesonide 100 micrograms or 200 micrograms.
PHARMACEUTICAL FORM
Inhalation powder
THERAPEUTIC INDICATIONS
Bronchial asthma
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The dosage of Pulmicort Turbuhaler is individual.
Initially, at the beginning of inhaled corticosteroid therapy, for
therapy during periods of severe asthma
or when scaling down or withdrawing oral corticosteroids the dosage
should be:
_Paediatric Population _
_Children aged 5 – 7 years:_ 100 - 400 micrograms per day, divided
into 2-4 inhalations. The full daily
dose may be given in one administration.
_Children aged 7 years and older:_ 100-800 micrograms per day, divided
into 2-4 inhalations. With daily
doses up to 400 micrograms the full dose may be given in one
administration.
_Adults:_ The normal dose range is 200-800 micrograms per day, divided
into 2-4 inhalations. In more
severe cases daily doses of up to 1600 micrograms may be needed. With
daily doses up to 400
micrograms the full dose may be given in one administration.
The maintenance dose should be the lowest possible.
It is possible that the patient will not taste or perceive any
medicine when Pulmicort Turbuhaler is
used; this is because such a small amount of substance is dispensed.
After a single dose an effect may be expected after a few hours. The
full therapeutic effect is only
achieved after several weeks of treatment. Treatment with Pulmicort
Turbuhaler is a prophylactic
therapy with no demonstrated effect on acute disorders.
Clinical trials indicate that a larger amount of budesonide is
deposited in the lungs when administered
with Pulmicort Turbuhaler, compared with Pulmicort pMDI. If a patient
in a stable phase is transferred
from Pulmicort pMDI to Pulmicort Turbuhaler a reduction in dose may
therefore be appropriate.
In patients in whom an increased therapeutic effect is desired, on
account of the lower risk of systemic
si